Publications by authors named "Nurzhanyat Ablaikhanova"

Article Synopsis
  • This study analyzed new circulating markers related to macrovascular complications (MVC) in patients with type 2 diabetes mellitus (T2DM) by comparing controls, patients with T2DM, and those with T2DM and vascular complications.
  • Results showed significant differences in the expression of specific microRNAs (miRs) between groups, particularly in miR-126a-3p, which was decreased in patients with vascular complications.
  • The study identified predictive models using various biomarkers, including HbA1c, creatinine, total cholesterol, and specific miRs, suggesting new avenues for understanding and predicting MVC in individuals with T2DM.
View Article and Find Full Text PDF

A common denominator of metabolic diseases, including type 2 diabetes Mellitus, dyslipidemia, and atherosclerosis, are elevated oxidative stress and chronic inflammation. These complex, multi-factorial diseases are caused by the detrimental interaction between the individual genetic background and multiple environmental stimuli. The cells, including the endothelial ones, acquire a preactivated phenotype and metabolic memory, exhibiting increased oxidative stress, inflammatory gene expression, endothelial vascular activation, and prothrombotic events, leading to vascular complications.

View Article and Find Full Text PDF

The development of type 2 diabetes mellitus (T2DM) vascular complications (VCs) is associated with oxidative stress and chronic inflammation and can result in endothelial dysfunctions. Circulating microRNAs play an important role in epigenetic regulation of the etiology of T2DM. We studied 30 healthy volunteers, 26 T2DM patients with no complications, and 26 T2DM patients with VCs, to look for new biomarkers indicating a risk of developing VCs in T2DM patients.

View Article and Find Full Text PDF

Pancreatic cancer (PC) is a lethal malignancy cancer, and its mortality rates have been increasing worldwide. Diagnosis of this cancer is complicated, as it does not often present symptoms, and most patients present an irremediable tumor having a 5-year survival rate after diagnosis. Regarding treatment, many concerns have also been raised, as most tumors are found at advanced stages.

View Article and Find Full Text PDF